Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (76,429)	$ (46,827)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	100	89
Stock-based compensation	5,530	2,089
Change in fair value of derivative liability	0	61
Noncash lease expense	290	211
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,166)	352
Other assets	0	64
Accounts payable	(3,741)	526
Accrued expenses	2,008	1,502
Operating lease liabilities	(54)	(319)
Net cash used in operating activities	(73,462)	(42,252)
Cash flows from investing activities:
Purchase of property and equipment	(89)	(151)
Net cash used in investing activities	(89)	(151)
Cash flows from financing activities:
Proceeds from sale of common stock in offerings, net of issuance costs paid	199,078	0
Proceeds from sale of pre-funded warrants in offerings, net of issuance costs paid	37,579	0
Proceeds from the issuance of common stock in pre-closing financing	0	53,500
Cash acquired in connection with the reverse recapitalization	0	97,403
Payment of reverse recapitalization transaction costs	0	(2,144)
Proceeds from stock option exercises	2,722	219
Net cash provided by financing activities	239,379	148,978
Net increase in cash, cash equivalents and restricted cash	165,828	106,575
Cash, cash equivalents and restricted cash at beginning of year	194,788	88,213
Cash, cash equivalents and restricted cash at end of year	360,616	194,788
Supplemental cash flow information
Cash paid for income taxes	112	0
Supplemental disclosure of non-cash activities
Purchases of property and equipment included in accounts payable and accrued expenses	13	0
Right-of-use assets obtained in exchange for new operating lease liabilities	1,106	0
Net decrease in right-of-use assets related to lease modifications and reassessment events	317	0
Net decrease in operating lease liabilities due to lease modifications and reassessment events	287	0
Receivable for proceeds from stock option exercises included in other current assets	41	0
Deferred issuance costs on sale of common stock and pre-funded warrants in offerings included in accounts payable and accrued expenses	225	5,792
Settlement of derivative liability upon issuance of common stock to Roche	$ 0	$ 6,511